Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Recommendation of “Hold” from Analysts

by · The Markets Daily

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.00.

A number of research firms recently commented on SRTS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd. HC Wainwright lowered their price target on shares of Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Finally, Lake Street Capital lowered their price target on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 8th.

Check Out Our Latest Stock Analysis on Sensus Healthcare

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC bought a new position in Sensus Healthcare in the 1st quarter valued at about $71,000. Bank of New York Mellon Corp increased its holdings in Sensus Healthcare by 3.9% in the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company’s stock valued at $672,000 after buying an additional 5,289 shares during the period. Larson Financial Group LLC bought a new position in Sensus Healthcare in the 1st quarter valued at about $26,000. Sachetta LLC increased its holdings in Sensus Healthcare by 4.1% in the 1st quarter. Sachetta LLC now owns 124,887 shares of the company’s stock valued at $591,000 after buying an additional 4,945 shares during the period. Finally, IFP Advisors Inc increased its holdings in Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock valued at $89,000 after buying an additional 5,100 shares during the period. 25.30% of the stock is owned by institutional investors.

Sensus Healthcare Stock Performance

NASDAQ SRTS opened at $3.19 on Tuesday. The firm has a 50-day moving average of $3.24 and a 200-day moving average of $4.12. The stock has a market cap of $52.44 million, a PE ratio of -53.17 and a beta of 1.38. Sensus Healthcare has a 52-week low of $3.03 and a 52-week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The company had revenue of $7.32 million for the quarter, compared to analyst estimates of $9.30 million. As a group, analysts predict that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Read More